Top Story

SUPPORT: Addition of olmesartan to therapy did not improve chronic HF outcomes

November 20, 2014

CHICAGO — When olmesartan was added to treatment with ACE inhibitors or beta-blockers, researchers reported no improved outcomes in patients with chronic HF and hypertension.

Treatment with all three medications in combination was linked with increased risk for all-cause mortality, adverse cardiac events and renal dysfunction, Yasuhiko Sakata, MD, PhD, said at the American Heart Association Scientific Sessions.

In the Journals

CABG outperformed PCI in patients with diabetes

November 20, 2014
PCI was associated with increases in mortality and a composite of adverse events compared with CABG in patients with diabetes, leading researchers to conclude that CABG…
More News Headlines »
CME
Challenges and Opportunities in the Treatment of Acute Ischemic Stroke: Key Points for the Emergency Physician

Challenges and Opportunities in the Treatment of Acute Ischemic Stroke

This activity is supported by an educational grant from Genentech.

According to the American Heart Association Heart Disease and Stroke Statistics – 2013 Update, approximately 795,000…
More »
Meeting News Coverage Video
Healio AHA2014 Underberg th

IMPROVE-IT results provide long-awaited answers

November 17, 2014
CHICAGO – In this video, James A. Underberg, MD, discusses the highly anticipated results of IMPROVE-IT, a trial…
More »
CME
Lipid Forum II Highlights

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »
morganatic-roan